Corbus Net Income vs Operating Income Analysis

CRBP Stock  USD 39.24  3.67  10.32%   
Corbus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corbus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corbus Pharmaceuticals is a good investment. Please check the relationship between Corbus Pharmaceuticals Net Income and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Net Income vs Operating Income

Net Income vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corbus Pharmaceuticals Net Income account and Operating Income. At this time, the significance of the direction appears to have totally related.
The correlation between Corbus Pharmaceuticals' Net Income and Operating Income is 0.99. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Corbus Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Corbus Pharmaceuticals' Net Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Corbus Pharmaceuticals Holding are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income i.e., Corbus Pharmaceuticals' Net Income and Operating Income go up and down completely randomly.

Correlation Coefficient

0.99
Relationship DirectionPositive 
Relationship StrengthVery Strong

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Corbus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Corbus Pharmaceuticals Holding operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Operating Income

Operating Income is the amount of profit realized from Corbus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Corbus Pharmaceuticals Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Corbus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
As of 03/29/2024, Selling General Administrative is likely to grow to about 14.6 B, while Issuance Of Capital Stock is likely to drop slightly above 231.9 K.

Corbus Pharmaceuticals fundamental ratios Correlations

-0.170.11-0.2-0.16-0.19-0.10.41-0.04-0.34-0.34-0.04-0.16-0.170.08-0.280.03-0.07-0.180.1-0.3-0.31-0.07-0.1-0.08-0.05
-0.170.770.20.640.840.67-0.44-0.690.520.760.690.980.770.820.630.80.821.00.210.760.180.870.780.790.53
0.110.770.160.670.470.760.06-0.880.310.390.750.730.820.890.410.950.880.750.480.41-0.310.670.770.80.73
-0.20.20.160.72-0.090.56-0.15-0.380.80.220.60.110.40.010.790.350.490.150.280.080.20.010.60.570.32
-0.160.640.670.720.230.89-0.3-0.740.850.590.860.540.770.510.880.760.920.60.460.460.030.450.880.890.73
-0.190.840.47-0.090.230.28-0.55-0.270.20.70.250.920.380.650.330.490.440.86-0.220.790.390.810.410.410.05
-0.10.670.760.560.890.28-0.24-0.670.770.560.750.580.670.720.810.720.940.620.280.49-0.260.360.960.960.69
0.41-0.440.06-0.15-0.3-0.55-0.24-0.14-0.54-0.89-0.06-0.47-0.07-0.13-0.5-0.01-0.24-0.450.39-0.56-0.64-0.34-0.24-0.23-0.05
-0.04-0.69-0.88-0.38-0.74-0.27-0.67-0.14-0.39-0.3-0.88-0.59-0.96-0.64-0.49-0.94-0.82-0.67-0.78-0.20.16-0.65-0.72-0.75-0.86
-0.340.520.310.80.850.20.77-0.54-0.390.650.680.420.50.320.940.40.720.480.10.480.250.190.80.780.47
-0.340.760.390.220.590.70.56-0.89-0.30.650.420.760.470.510.660.440.630.77-0.090.690.460.620.580.580.42
-0.040.690.750.60.860.250.75-0.06-0.880.680.420.570.860.590.690.840.880.650.60.330.070.510.830.840.76
-0.160.980.730.110.540.920.58-0.47-0.590.420.760.570.670.820.540.760.750.980.060.80.240.880.690.70.4
-0.170.770.820.40.770.380.67-0.07-0.960.50.470.860.670.60.580.910.830.750.730.340.00.720.720.740.86
0.080.820.890.010.510.650.72-0.13-0.640.320.510.590.820.60.370.770.810.80.080.58-0.240.60.760.780.51
-0.280.630.410.790.880.330.81-0.5-0.490.940.660.690.540.580.370.520.770.590.210.570.190.40.860.840.46
0.030.80.950.350.760.490.72-0.01-0.940.40.440.840.760.910.770.520.880.780.570.39-0.070.750.760.790.75
-0.070.820.880.490.920.440.94-0.24-0.820.720.630.880.750.830.810.770.880.780.40.56-0.10.590.950.970.76
-0.181.00.750.150.60.860.62-0.45-0.670.480.770.650.980.750.80.590.780.780.190.760.210.890.730.750.5
0.10.210.480.280.46-0.220.280.39-0.780.1-0.090.60.060.730.080.210.570.40.19-0.23-0.210.360.280.310.74
-0.30.760.410.080.460.790.49-0.56-0.20.480.690.330.80.340.580.570.390.560.76-0.230.220.590.580.570.05
-0.310.18-0.310.20.030.39-0.26-0.640.160.250.460.070.240.0-0.240.19-0.07-0.10.21-0.210.220.29-0.12-0.14-0.19
-0.070.870.670.010.450.810.36-0.34-0.650.190.620.510.880.720.60.40.750.590.890.360.590.290.470.50.44
-0.10.780.770.60.880.410.96-0.24-0.720.80.580.830.690.720.760.860.760.950.730.280.58-0.120.471.00.63
-0.080.790.80.570.890.410.96-0.23-0.750.780.580.840.70.740.780.840.790.970.750.310.57-0.140.51.00.66
-0.050.530.730.320.730.050.69-0.05-0.860.470.420.760.40.860.510.460.750.760.50.740.05-0.190.440.630.66
Click cells to compare fundamentals

Corbus Pharmaceuticals Account Relationship Matchups

Corbus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding2.1M2.6M4.1M4.2M4.3M2.9M
Total Assets49.1M102.3M107.7M66.3M28.3M50.5M
Short Long Term Debt Total9.4M26.8M26.6M25.1M20.9M11.1M
Other Current Liab22.4M797K133.7K6.0M11.1M5.9M
Total Current Liabilities34.9M31.9M17.0M12.6M31.9M16.9M
Total Stockholder Equity6.2M45.3M69.1M33.0M(6.9M)(6.6M)
Net Debt(22.3M)(58.6M)1.6M8.1M7.0M7.3M
Retained Earnings(192.8M)(304.1M)(349.7M)(392.1M)(436.7M)(414.8M)
Accounts Payable11.1M7.4M1.8M2.2M3.2M4.0M
Cash31.7M85.4M25.0M17.0M13.9M13.2M
Cash And Short Term Investments31.7M85.4M97.6M59.2M21.1M20.0M
Common Stock Total Equity5.6K5.7K6.5K9.9K11.4K11.9K
Liabilities And Stockholders Equity49.1M102.3M107.7M66.3M28.3M50.5M
Non Current Liabilities Total8.1M25.1M21.6M20.7M3.3M3.1M
Other Current Assets6.4M3.7M2.4M791.6K2.4M2.3M
Other Stockholder Equity199.0M349.4M418.9M425.2M429.8M216.4M
Total Liab43.0M57.0M38.6M33.3M35.2M25.1M
Total Current Assets38.2M92.1M100.2M60.2M23.5M46.1M
Short Term Debt1.3M1.7M5.0M4.4M17.6M18.5M
Common Stock6.5K9.9K12.5K417.0442.0419.9
Net Tangible Assets6.2M45.3M69.1M33.0M37.9M32.1M
Property Plant And Equipment Net10.9M9.3M7.0M5.5M4.0M4.6M
Non Current Assets Total11.0M10.2M7.5M6.1M4.7M4.9M
Non Currrent Assets Other85.0K234.0K46.4K155.3K212.8K223.4K
Retained Earnings Total Equity(65.7M)(121.4M)(192.8M)(304.1M)(273.7M)(260.0M)
Capital Surpluse123.5M148.9M199.0M349.4M401.8M421.9M
Property Plant And Equipment Gross10.9M9.3M7.0M5.5M7.6M5.0M
Short Long Term Debt752.7K710.2K3.9M3.1M16.2M17.0M
Accumulated Other Comprehensive Income(666.6K)(1.4M)(62.4K)(126.1K)(1.6K)(1.6K)
Property Plant Equipment5.1M9.3M7.0M5.5M6.3M3.9M

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Corbus Stock

  0.88KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.87MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.86MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.83VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.82ME 23Andme HoldingPairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Corbus Stock analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.31)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.60)
Return On Equity
(3.42)
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.